In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...
The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...
Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback